AlzeCure signs collaboration, out-licensing deal with Lilly for Alzheimer's drug
AlzeCure signs collaboration, out-licensing deal with Lilly for Alzheimer's drug June 9 (Reuters) - AlzeCure Pharma ALZCUR.ST said on Tuesday it had entered a collaboration and out-licensing agreement with Eli Lilly LLY.N for the global rights of an Alzheimer's treatment in a deal that could exceed $1 billion in total value.
AlzeCure develops small-molecule drug candidates for central nervous system diseases with a focus on Alzheimer's disease and pain.
The deal is for the global rights to AlzeCure's drug candidate Alzstatin ACD680, currently in preclinical development
AlzeCure will receive an upfront payment of $10 million, development and commercial milestone payments, and tiered mid-single digit royalties on sales
Alzstatin compounds are hoped to be used to counteract re-accumulation of harmful amyloid buildup in the brain and in the long term may be used to help prevent Alzheimer’s disease, CEO Martin Jönsson said
(Reporting by Vera Dvorakova, Editing by Milla Nissi-Prussak)
((vera.dvorakova@thomsonreuters.com))
Recent news on Eli Lilly and Co
See all newsAntares Therapeutics signs potential $1.9 billion cancer drug deal with Novartis
Absci rises on positive hair-loss drug data
China approval for Eli Lilly GLP-1 pill to come as soon as 2026, executive says
HK-listed Abbisko climbs most in 12 weeks on Eli Lilly tie-up
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly (updated)